Upadacitinib

乌帕替尼

Report date: 2026/05/18 20:02:07
NME

Base Information

Drug NameUpadacitinib
Drug Alias NameUpadacitinibum乌西替尼Upadacitinib tartrateUpadicitinib hemihydrateUpadacitinib extended release +[12] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase JAK1 inhibitors
TargetsTyrosine-protein kinase JAK1
Therapy Area/IndicationsNon-radiographic axial spondyloarthritisVitiligoAlopecia Areata +[21] 
Global Approved IndicationsDermatitis, AtopicArthritis, Rheumatoid
Approved Indications in ChinaDermatitis, Atopic
Original Approved Country/TerritoryUnited States
Original Approved Date2019/08/16
Country/TerritoryCzechiaBelgiumBosnia and Herzegovina +[60] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesAbbott Laboratories
China Registration ClassN/A

Develop Information

Active CompaniesThe People'S Hospital Of QuzhouPeking University People'S HospitalAbbvie Gk +[10] 
Inactive CompaniesN/A
Active IndicationsNon-radiographic axial spondyloarthritisVitiligoAlopecia Areata +[20] 
Inactive IndicationsSleep Wake Disorders

Other Information

ATC CodeL04AF03
Related LinksWikipediaDrugBankKEGG